Recent Updates
Recently added Catalysts
CDNA Positive Sentiment

CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026

Thursday, July 16, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CareDx, Inc. will announce its financial results for the second quarter of 2026 on July 30, 2026, after market close. The company, known for its work in precision medicine diagnostics, will also host a conference call and webcast at 1:30 p.m. PT. This event will provide stakeholders with insights into the company's performance.
Price reaction · baseline $29.75 (2026-07-15 close) · hit pre-market · clean, no other CDNA news in the window
day 0 close · peak
+35.6%
day 1
+33.5%
day 3
+29.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • CareDx is a leading company in precision medicine diagnostics.
  • The upcoming financial report indicates growth and transparency.
  • The scheduled conference call allows for direct communication with stakeholders.

Full Press Release Details

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the conference call can be accessed on the Events & Presentations section of Car

Frequently Asked Questions

When will CareDx report its Q2 2026 financial results?

CareDx will report its Q2 2026 financial results on July 30, 2026.

What time is the CareDx conference call?

The conference call will be held at 1:30 p.m. PT on July 30, 2026.

Where can I access the CareDx conference call?

The conference call can be accessed via the Events & Presentations section on CareDx's website.

ShareAdd on Google
Tags: CDNA Viatris Investor Conferences Healthcare CareDx financial results Q2 2026 conference call
Last updated: Jul 16, 2026

Biotech snapshot

Cash runway
$374M liquidity · $0M/mo burn
Low dilution risk